Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capivasertib + abemaciclib + fulvestrant
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
**capivasertib + abemaciclib + fulvestrant** is an investigational combination therapy comprising three agents: - **Capivasertib**: a small molecule inhibitor of AKT, a kinase in the PI3K/AKT signaling pathway, which is frequently dysregulated in breast cancer and contributes to cell growth, survival, and endocrine resistance. - **Abemaciclib**: a small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which block cell cycle progression from G1 to S phase, inhibiting tumor cell proliferation. - **Fulvestrant**: a selective estrogen receptor degrader (SERD), which binds, blocks, and induces degradation of the estrogen receptor, preventing estrogen-driven cancer cell growth. This triplet regimen is being studied in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced, unresectable or metastatic breast cancer, including patients with prior resistance to endocrine therapy and/or CDK4/6 inhibitors. The combination targets multiple complementary pathways believed to drive breast cancer progression and therapeutic resistance[1][5].
- Other names
- capivasertib + abemaciclib + fulvestrant
02
Targets
ER (Estrogen receptor)CDK6 (Cyclin-dependent kinase 6)DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)HIPK2 (Homeodomain-interacting protein kinase 2)AKT2 (Rac-beta serine/threonine-protein kinase)CDK4 (Cyclin-dependent kinase 4)HIPK3
Beyond the preview
Go deeper on capivasertib + abemaciclib + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capivasertib + abemaciclib + fulvestrant.